Eli Lilly expects to provide results from a study in people with obesity and osteoarthritis of the knee in 2025.

January 2025 kicked off with a wave of impactful biotech deals, setting the stage for an exciting year of innovation.

Eli Lilly & Co.’s full-year earnings forecast came in line with analysts’ estimates as the company works to fix inventory ...

In the first half of 2025, Ozempic developer Novo Nordisk in Bagsværd, Denmark, expects results from a second phase III trial ...

Novo Nordisk defended its next-generation obesity drug candidate CagriSema on Wednesday following late-stage trial data ...

Eli Lilly investors and analysts said they want to hear details from the company on how exactly it plans to grow U.S. sales ...

Indiana's workforce is feeling pressure to return to the office, but a good portion of employees still like hybrid work. Is ...

An international trial is testing remternetug in young adults at genetic risk for early-onset Alzheimer’s. The study aims to ...

Amgen Inc.’s disclosed that US regulators paused the study of an early-stage obesity drug, a lucrative market the company is trying to crack.Most Read from BloombergCitadel to Leave Namesake Chicago T ...

Body-weight cycling, sometimes referred to as yo-yo dieting, may be harmful to the kidneys for people with type 1 diabetes, ...

GLP-1 receptor agonists were more cardioprotective in younger people, but reduced HbA1c more with age. The age of type 2 ...